CureVac
Industry / private company
Location:
Tübingen,
Germany (DE)
ISNI: 0000000453454022
ROR: https://ror.org/02q3n2241
IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL (2021)
Codo P, Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, et al.
Conference contribution
Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008 (2021)
Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, Mohr P, et al.
Conference contribution
A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors (2019)
Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al.
Conference contribution
A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (2019)
Krauss J, Eigentler T, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al.
Conference contribution
Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors (2019)
Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al.
Conference contribution
Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- nd RIG-1 agonist in patients with advanced solid tumors (2018)
Terheyden P, Weishaupt C, Heinzerling L, Klinkhardt U, Krauss J, Mohr P, Kiecker F, et al.
Conference contribution